Showing 5561-5570 of 5643 results for "".
- Cincinnati Eye Institute Launches CEI Vision Partnershttps://modernod.com/news/cincinnati-eye-institute-launches-cei-vision-partners/2480134/Cincinnati Eye Institute (CEI) announced the launch of CEI Vision Partners (CEIVP), a new management services organization made possible with the support of Revelstoke Capital Partners, a Denver-based private equity firm. “For more than 70 years, CEI has been growing as a world-class
- ThromboGenics Enrolls First Patient in Phase 1 Clinical Study Evaluating THR-149 for Treatment of DMEhttps://modernod.com/news/thrombogenics-enrolls-first-patient-in-phase-1-clinical-study-evaluating-thr-149-for-treatment-of-dme/2480139/ThromboGenics NV announced that it has successfully enrolled the first patient in a phase 1 open-label, multicenter, dose escalation study evaluating the safety of THR-149 in the treatment of DME (NCT03511898). THR-149 is a novel plasma kallikrein inhibitor generated using Bicycle Therapeu
- Rayner Receives CE Mark for Its Hydrophobic Fully Preloaded IOL Injection Systemhttps://modernod.com/news/rayner-receives-ce-mark-for-its-hydrophobic-fully-preloaded-iol-injection-system/2480142/Rayner has received European CE Mark for its first hydrophobic fully preloaded IOL injection system. The RayOne Hydrophobic IOL is made of a new proprietary material that is glistening-free, with a patented “Cornerstone” lens shape for stability during lens delivery and post-implantat
- Gene Therapies That Could Transform Diseases Get Easier FDA Pathhttps://modernod.com/news/gene-therapies-that-could-transform-diseases-get-easier-fda-path/2480144/New therapies that may cure diseases caused by defective genes will get a faster path to approval by U.S. regulators, part of an effort by the FDA to keep pace with one of biotechnology’s fastest-growing fields, according to a Bloomberg
- Researchers Identify Genetic Variants that May Predict Glaucoma Riskhttps://modernod.com/news/researchers-identify-genetic-variants-that-may-predict-glaucoma-risk/2480146/A study led by scientists from King’s College London, University College London, Massachusetts Eye and Ear, and Harvard Medical School has identified 133 genetic variants that could help predict the risk of developing glaucoma, the world’s leading cause of incurable blindness.
- Aerie Submits New Drug Application to FDA for Roclatanhttps://modernod.com/news/aerie-submits-new-drug-application-to-fda-for-roclatan/2480148/Aerie Pharmaceuticals announced the submission of its new drug application (NDA) to the FDA for Roclatan (netarsudil/latanoprost ophthalmic solution) .02%/.005%. Roclatan is a once-daily eye drop designed to reduce IOP in patients with glaucoma or ocular hypertension. It is a fixed dose combinati
- Genome Surgery for Eye Disease Moves Closer to Realityhttps://modernod.com/news/genome-surgery-for-eye-disease-moves-closer-to-reality/2480154/Researchers from Columbia University have developed a new technique for the powerful gene editing tool CRISPR to restore retinal function in mice afflicted by a degenerative retinal disease, retinitis pigmentosa. This is the first time researchers have successfully app
- Kala Pharmaceuticals Strengthens Commercial Organization in Preparation for First Product Launchhttps://modernod.com/news/kala-pharmaceuticals-strengthens-commercial-organization-in-preparation-for-first-product-launch/2480159/Kala Pharmaceuticals announced the following key commercial hires in preparation for the potential approval and launch of Inveltys, a twice-daily steroid eye drop in development for the treatment of inflammation and pain following ocular surgery: Kathleen McCann Kline, Vice President
- Eye Health America Appoints Cathleen McCabe, MD, as Chief Medical Officerhttps://modernod.com/news/eye-health-america-appoints-cathleen-mccabe-md-as-chief-medical-officer/2480162/Eye Health America (EHA) has appointed Cathleen McCabe, MD, as its chief medical officer. As the newest member of EHA’s executive leadership team, Dr. McCabe will be responsible for the development, implementation, and continuation of best practices across EHA’s group practices and ambulatory sur
- Sylentis Announces New Data on the Treatment of Allergic Conjunctivitishttps://modernod.com/news/sylentis-announces-new-data-on-the-treatment-of-allergic-conjunctivitis/2480172/At the ARVO meeting, Sylentis presented preclinical results on its RNAi therapy, demonstrating how SYL116011 acts on seasonal ocular allergies SYL116011, which is being researched for ocular allergies caused by pollen, reduces the symptoms related to allergy, such as swelling and tearing,